# Natalizumab in Recurrent, Refractory or Progressive Pulmonary Metastatic Osteosarcoma

> **NCT03811886** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Case Comprehensive Cancer Center**

## Conditions studied

- Pulmonary Metastatic Osteosarcoma (pOS)

## Interventions

- **DRUG:** Natalizumab

## Key facts

- **NCT ID:** NCT03811886
- **Lead sponsor:** Case Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-12-01
- **Primary completion:** 2025-12-01
- **Final completion:** 2026-10-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No accruals
- **Last updated:** 2025-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03811886

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03811886, "Natalizumab in Recurrent, Refractory or Progressive Pulmonary Metastatic Osteosarcoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03811886. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*